August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
The presidential keynote address at ASCO 2015 was presented by Michael E. Porter, PhD, MBA, Bishop William Lawrence University Professor, Harvard Business School, Boston, who started the value discussions a decade ago.
Immunotherapy with the recently approved anti–PD-1 inhibitor nivolumab prolonged survival in patients with nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy for disease progression with standard platinum-based therapy.
At ASCO 2015, Leonard B. Saltz, MD, was given a prominent soapbox from which to voice his concerns about the rising cost of cancer care.
The oncology pipeline remains robust, especially as the industry embraces the promise of immune checkpoint inhibitors.
- First HDAC Inhibitor, Panobinostat, Approved for the Treatment of Patients with Multiple Myeloma
- Palbociclib Approved for Metastatic Breast Cancer in Postmenopausal Women
- FDA Expedites Approval of Lenvatinib for Refractory Differentiated Thyroid Cancer
- Lenalidomide plus Dexamethasone Receives Expanded Indication for Patients with Newly Diagnosed Myeloma
- Nivolumab First Immunotherapy to Get FDA Approval for Metastatic Lung Cancer
Contrary to the notion that chemotherapy infusion has largely become a hospital-based procedure, analysts from Aetna found that approximately 75% of their patients still receive chemotherapy in a community oncology practice setting.
Leonard B. Saltz, MD, wants the new checkpoint inhibitors to be available to his patients, but he questions how society will pay for them.
It comes as no surprise: targeted therapies now dominate anticancer drug spending in the United States, according to a team of researchers from several major cancer centers.
“Chemotherapy plus bevacizumab costs less and achieves very similar survival and quality-adjusted survival as chemotherapy plus cetuximab for first-line treatment of KRAS wild-type metastatic colorectal cancer,” according to Deborah Schrag, MD, MPH, who presented the analysis at ASCO 2015.
Necitumumab is currently being considered by the US Food and Drug Administration’s (FDA) Oncology Drugs Advisory Committee for the treatment of metastatic squamous-cell lung cancer.
Page 1 of 4
Results 1 - 10 of 37
Results 1 - 10 of 37